Reuters logo
BRIEF-Eiger Biopharmaceuticals updates on hypoglycemia study
December 12, 2016 / 1:18 PM / 9 months ago

BRIEF-Eiger Biopharmaceuticals updates on hypoglycemia study

Dec 12 (Reuters) - Eiger Biopharmaceuticals Inc

* Eiger biopharmaceuticals inc - clinical and regulatory advances in development of exendin 9-39 for treatment of post-bariatric hypoglycemia (pbh)

* Eiger biopharmaceuticals inc - all doses administered were well-tolerated with headache or nausea as only reported adverse events in program Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below